文献速递类风湿关节炎其他结缔组织病

利妥昔单抗或TNFi作为首个生物制剂治疗RA-ILD患者的死亡率比较

Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic.
PubMed 文献 · RMD Open · 2017-07-13

基于英国风湿病学会生物制剂注册队列,比较43例接受利妥昔单抗(RTX)和309例接受TNFi作为首个生物制剂的类风湿关节炎相关间质性肺病(RA-ILD)患者的死亡率。RTX组死亡率较高但校正后死亡风险减半(HR 0.53,95%CI 0.26-1.10),差异无统计学意义;两组ILD作为根本死因的比例相近。

要点

  • RTX组粗死亡率为94.8/1000人年,TNFi组为53.0/1000人年。
  • 校正后RTX组死亡风险为TNFi组的一半(HR 0.53,95%CI 0.26-1.10),但无统计学意义。
  • ILD为根本死因在RTX组占1/7(14%),TNFi组占12/76(16%)。

核心结论

  • RA-ILD患者接受RTX作为首个生物制剂较TNFi死亡率更低但差异无统计学意义。
  • 缺乏ILD严重度或亚型信息,无法确定活动性关节炎RA-ILD患者的最佳药物选择。

研究设计与样本

  • 基于英国风湿病学会类风湿关节炎生物制剂注册队列的观察性研究。
  • 纳入RA-ILD患者,RTX组43例,TNFi组309例。
  • 计算死亡率并使用Cox回归进行风险比较,同时检查死因及死亡证书中ILD记录频率。

主要发现

  • RTX组疾病病程更短且残疾程度更轻。
  • RTX组死亡率为94.8(95%CI 74.4-118.7)/1000人年,TNFi组为53.0(95%CI 22.9-104.6)/1000人年。
  • 校正后RTX组死亡风险减半(HR 0.53,95%CI 0.26-1.10),差异无统计学意义。
  • ILD为根本死因在RTX组7例死亡中占1例(14%),TNFi组76例死亡中占12例(16%)。

临床怎么用

  • 对于RA-ILD患者,RTX相较TNFi未显示显著生存劣势,但需结合ILD严重度与亚型个体化选择。
  • 临床决策时需关注ILD严重度与亚型信息以优化生物制剂选择。

局限性

  • 缺乏ILD严重度或亚型信息,限制药物最佳选择的结论。
  • 观察性研究设计,可能存在混杂偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Guidelines cautioned prescribing of tumour necrosis factor inhibitors (TNFi) to patients with rheumatoid arthritis and interstitial lung disease (RA-ILD) after reports of new or worsening of ILD. Less is known about outcomes among patients with RA-ILD who receive rituximab (RTX). This study compares mortality in patients with RA-ILD who received RTX or TNFi as their first biologic. METHODS: Participants with RA-ILD recruited to the British Society for Rheumatology Biologics Register for RA were included. Death rates were calculated and risk comparisons were made using Cox regression. Causes of death, including the frequency in which ILD was recorded on death certificates were examined. RESULTS: 43 patients on RTX and 309 on TNFi were included. RTX recipients had shorter disease duration and less disability. Death rates were 94.8 (95%CI: 74.4 to 118.7) and 53.0 (22.9 to 104.6) per 1000 person years, respectively. The adjusted mortality risk was halved in the RTX cohort, but the difference was not statistically significant (HR 0.53, 95% CI: 0.26 to 1.10). ILD was the underlying cause of death in 1 of 7 RTX deaths (14%) and 12 of 76 TNFi deaths (16%). CONCLUSIONS: Patients with RA-ILD who received RTX had lower mortality rates compared to TNFi. The absence of information on ILD severity or subtype prevents conclusions of which drug represents the best choice in patients with RA-ILD and active arthritis.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Druce KL, Iqbal K, Watson KD, et al. Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic. RMD Open. 2017. PMID: 28955489. doi:10.1136/rmdopen-2017-000473

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。